Cybin Inc (CYBN)

$8.16 +0.31 (3.95%)
Market Cap 205.53M
Revenue (ttm) 0.00
Net Income (ttm) -81.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,039,200
Avg Vol 879,698
Day's Range N/A - N/A
Shares Out 25.19M
Stochastic %K 95%
Beta 0.67
Analysts Strong Sell
Price Target $45.00

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology
Sector: Healthcare
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
1iquid
1iquid Dec. 25 at 2:11 PM
💎 Liquid® Live Actionable Trade Asset: $CYBN Contracts: $CYBN August 21, 2026 $12 Calls Scale in: $1.36- $1.66 Scale out: $5.29-$9.07 Profit Potential : 327% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
blago04
blago04 Dec. 24 at 5:05 PM
$CYBN who here is also interested in CMPS? Thinking of starting to build a position there first with this as a secondary for some added "torque"
1 · Reply
microdoseme
microdoseme Dec. 24 at 5:00 PM
$CYBN Must have some ambitous data forthcoming. Happy Holidays to all.
0 · Reply
biochirp
biochirp Dec. 24 at 3:59 PM
$CYBN holding for data readout, nice move tho
0 · Reply
TrendDecoded
TrendDecoded Dec. 24 at 4:58 AM
$GOOG $CMPS $CYBN Google is the only company that owns the entire AI stack. 1. Chips: TPUs 2. Infrastructure: Google Cloud 3. Foundation Models: Deepmind 4. Applications: Gemini Every layer matters. The more layers you own, the bigger your advantage. In-depth analysis and sharing of practical investment strategies, interpreting real-time market trends @TrendDecoded
1 · Reply
brunoq14
brunoq14 Dec. 24 at 4:49 AM
$CMPS $CYBN moves to Nasdaq January 5, under new symbol HELP.
0 · Reply
brunoq14
brunoq14 Dec. 24 at 4:44 AM
$CYBN Moves to Nasdaq January 5, trading under new symbol: HELP.
0 · Reply
RkyMtnChi
RkyMtnChi Dec. 24 at 12:50 AM
$CYBN I've admittedly flipped this stock more times than I can count over the last few years, knowing that approval was still a ways down the road. But long-term, it's still the ace in my hand and I'm done with flipping shares, as their trials continue to produce great results and the light at the end of the tunnel draws nearer. My only regret is that I didn't buy more shares when it dipped back into the 5s. If it dips again, I'll fix that mistake.
2 · Reply
Mastacash
Mastacash Dec. 24 at 12:28 AM
$JMIA $CYBN I was calling a bottom in this name last year as the stock was at $2, this board was dead and so was the stock. Now it’s at $13 and will run to the $20S next year if growth continues. For anyone interested my new buy next year is $CYBN, a small cap psychedelic stock that’s is deeply undervalued but the science and results so far have been impressive, as well as the shift in regulations for alternative medicine (maryj going to sched 3) if you ever heard RFK jr speak, Psilocybin is next. Cheers.
0 · Reply
BSwalks
BSwalks Dec. 23 at 10:41 PM
$ATAI gets the big news. $CYBN and $CMPS get the big moves. 🤔
0 · Reply
Latest News on CYBN
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 7 days ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 3:11 PM EST - 6 weeks ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 6 weeks ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 6 weeks ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 7 weeks ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 2 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 3 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 3:59 PM EDT - 3 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 3 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 4 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 4 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 4 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 6 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 6 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 6 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 6 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 7 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 8 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Feb 10, 2025, 9:48 PM EST - 11 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 15, 2025, 12:07 PM EST - 1 year ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 5:00 PM EST - 1 year ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

1iquid
1iquid Dec. 25 at 2:11 PM
💎 Liquid® Live Actionable Trade Asset: $CYBN Contracts: $CYBN August 21, 2026 $12 Calls Scale in: $1.36- $1.66 Scale out: $5.29-$9.07 Profit Potential : 327% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
blago04
blago04 Dec. 24 at 5:05 PM
$CYBN who here is also interested in CMPS? Thinking of starting to build a position there first with this as a secondary for some added "torque"
1 · Reply
microdoseme
microdoseme Dec. 24 at 5:00 PM
$CYBN Must have some ambitous data forthcoming. Happy Holidays to all.
0 · Reply
biochirp
biochirp Dec. 24 at 3:59 PM
$CYBN holding for data readout, nice move tho
0 · Reply
TrendDecoded
TrendDecoded Dec. 24 at 4:58 AM
$GOOG $CMPS $CYBN Google is the only company that owns the entire AI stack. 1. Chips: TPUs 2. Infrastructure: Google Cloud 3. Foundation Models: Deepmind 4. Applications: Gemini Every layer matters. The more layers you own, the bigger your advantage. In-depth analysis and sharing of practical investment strategies, interpreting real-time market trends @TrendDecoded
1 · Reply
brunoq14
brunoq14 Dec. 24 at 4:49 AM
$CMPS $CYBN moves to Nasdaq January 5, under new symbol HELP.
0 · Reply
brunoq14
brunoq14 Dec. 24 at 4:44 AM
$CYBN Moves to Nasdaq January 5, trading under new symbol: HELP.
0 · Reply
RkyMtnChi
RkyMtnChi Dec. 24 at 12:50 AM
$CYBN I've admittedly flipped this stock more times than I can count over the last few years, knowing that approval was still a ways down the road. But long-term, it's still the ace in my hand and I'm done with flipping shares, as their trials continue to produce great results and the light at the end of the tunnel draws nearer. My only regret is that I didn't buy more shares when it dipped back into the 5s. If it dips again, I'll fix that mistake.
2 · Reply
Mastacash
Mastacash Dec. 24 at 12:28 AM
$JMIA $CYBN I was calling a bottom in this name last year as the stock was at $2, this board was dead and so was the stock. Now it’s at $13 and will run to the $20S next year if growth continues. For anyone interested my new buy next year is $CYBN, a small cap psychedelic stock that’s is deeply undervalued but the science and results so far have been impressive, as well as the shift in regulations for alternative medicine (maryj going to sched 3) if you ever heard RFK jr speak, Psilocybin is next. Cheers.
0 · Reply
BSwalks
BSwalks Dec. 23 at 10:41 PM
$ATAI gets the big news. $CYBN and $CMPS get the big moves. 🤔
0 · Reply
firetypecracker
firetypecracker Dec. 23 at 8:56 PM
$CYBN Has broken through 100 day resistance and then some. Up over 10% now...
0 · Reply
Marcelline
Marcelline Dec. 23 at 8:55 PM
$CYBN it’s only Monday…
1 · Reply
BobJohnBuoy666
BobJohnBuoy666 Dec. 23 at 8:47 PM
$CYBN expanding price, volume, and momentum. The stars have aligned
0 · Reply
firetypecracker
firetypecracker Dec. 23 at 8:34 PM
$CYBN Listen to this guy...
1 · Reply
tomtom101
tomtom101 Dec. 23 at 8:18 PM
$CYBN let go bulls!
0 · Reply
Mastacash
Mastacash Dec. 23 at 7:59 PM
$CYBN calling all $ONDS bulls. REMEMBER ME? The bullish guy providing analysis when the stock was at 50cent, and now at $9. I found our next multi bagger in $CYBN, do your own DD but I encourage you to check it out. Oh ya, I still hold a large sum of $ONDS as well. Cheers.
1 · Reply
topstockalerts
topstockalerts Dec. 23 at 7:43 PM
$CYBN trying to consolidate here..
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Dec. 23 at 7:23 PM
Top 5 stocks going into 2026 $BABA $CMPS $RIVN $EKSO $CYBN
1 · Reply
Tyuop
Tyuop Dec. 23 at 7:05 PM
$CYBN
0 · Reply
Mastacash
Mastacash Dec. 23 at 6:26 PM
$CYBN Last year I was pounding the table on $ONDS and $JMIA, both have been multibaggers, check my history posts if you don’t believe me. Next year I’m just as bullish on $CYBN, the fundamentals and technicals are lining up for a multibagger year.
2 · Reply
Lrussell234
Lrussell234 Dec. 23 at 5:12 PM
$CYBN Squeeze bait jump. 👍
0 · Reply
microdoseme
microdoseme Dec. 23 at 4:15 PM
$CYBN 2026 year of the Psychedelics. Relief for millions.
0 · Reply